STOCK TITAN

Tonix Pharmaceut - TNXP STOCK NEWS

Welcome to our dedicated page for Tonix Pharmaceut news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceut stock.

Tonix Pharmaceuticals Holding Corp (TNXP) is a clinical-stage biopharmaceutical company developing innovative therapeutics for central nervous system disorders, immunology, and infectious diseases. This page provides timely updates on TNXP's clinical trials, regulatory milestones, and strategic initiatives.

Key resources for investors include press releases covering product development progress, partnership announcements, and financial reports. Our curated news collection helps track TNXP's pipeline candidates like TNX-102 SL for fibromyalgia and Tonmya™ for PTSD management.

Stay informed about developments in migraine therapeutics, rare disease research, and vaccine programs. Content categories include FDA communications, clinical trial results, intellectual property updates, and market expansion activities.

Bookmark this page for direct access to verified TNXP updates. Check regularly for new developments in biopharmaceutical innovation impacting patient care and treatment paradigms.

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) plans to develop TNX-102 SL as a potential treatment for Long COVID, officially known as Post-Acute Sequelae of COVID-19 (PASC). Over 30% of COVID-19 patients develop chronic symptoms such as fatigue and brain fog. An FDA pre-IND meeting is scheduled for Q3 2021 to discuss the clinical development plan. TNX-102 SL is also in mid-Phase 3 for fibromyalgia, with results expected in Q3 2021 and Q1 2022. The drug aims to improve sleep quality, potentially addressing the core symptoms of Long COVID.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
covid-19
-
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 8:00 a.m. ET. Investors can arrange virtual meetings through the conference coordinator. A webcast of the presentation will be accessible on Tonix's website. The company is focused on developing small molecules and biologics for CNS and immunology conditions. Its lead candidate, TNX-102 SL, is in mid-Phase 3 for fibromyalgia, with interim data expected in Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
conferences
-
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will participate in the BIO Digital Conference on June 10-11 and 14-18, 2021. The company's presentation will be available on demand for registered attendees. Tonix focuses on developing therapeutics for CNS and immunology, with lead candidates TNX-102 SL for fibromyalgia and TNX-1800 for COVID-19 vaccination. Interim results from their second Phase 3 study for TNX-102 SL are expected in Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Tonix Pharmaceuticals announced positive results from its Phase 3 RELIEF study of TNX-102 SL for fibromyalgia, significantly reducing daily pain compared to placebo (p=0.01) and improving key secondary endpoints like sleep quality and fatigue. The treatment was well tolerated, showing no side effects common with oral fibromyalgia treatments. The company expects interim analysis results for its ongoing confirmatory study, RALLY, in Q3 2021, followed by topline data in Q1 2022. TNX-102 SL has a favorable patent protection until 2034/2035.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) announced plans to present two posters at the 2021 ASCP Annual Meeting from June 1-4, 2021. The presentations will focus on TNX-102 SL for treating fibromyalgia and PTSD, showcasing results from their clinical trials. The first poster, on June 2, will detail a Phase 3 trial's positive results in fibromyalgia, while the second, on June 3, will analyze PTSD outcomes. Tonix aims to release interim data from its second Phase 3 study in Q3 2021 and topline data in Q1 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman will present at the Q2 Investor Summit Virtual Conference on May 17, 2021, at 3:30 p.m. ET. Investors can arrange virtual meetings with management through the conference coordinator. Tonix focuses on developing therapies for CNS and immunology, with lead candidates including TNX-102 SL for fibromyalgia and TNX-1800, a COVID-19 vaccine. Positive data from animal studies of TNX-1800 were reported in early 2021. Interim data from the RALLY study is expected in Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) reported Q1 2021 financial results, achieving a cash balance of approximately $164 million, up from $77.1 million at the end of 2020. The company experienced a net loss of $20.7 million, or $0.07 per share, compared to $9 million a year prior. Key updates include positive animal study results for its COVID-19 vaccine candidate TNX-1800 and ongoing development of its CNS programs, with three entering Phase 2 trials this year. An interim analysis for its fibromyalgia treatment, TNX-102 SL, is expected in Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
-
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will present and join a panel discussion at the 4th Annual Neuroscience Innovation Forum, taking place April 28-30, 2021.

The panel, titled Pain, Migraine & Addiction, is scheduled for April 29 from 11:45 a.m. to 12:45 p.m. ET. The presentation will be available on demand during the event and afterwards on the Tonix website. Tonix focuses on developing therapies for CNS conditions, with key candidates like TNX-102 SL for fibromyalgia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
-
Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) has entered a global licensing agreement with OyaGen for TNX-3500 (sangivamycin), an antiviral drug targeting SARS-CoV-2. Initial studies indicate TNX-3500 exhibits approximately 65 times greater potency than remdesivir against SARS-CoV-2 and shows additive effects when combined with it. This drug is in pre-Investigational New Drug (IND) development and has demonstrated safety in previous human studies. Tonix aims to advance TNX-3500 for regulatory approval in treating COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.2%
Tags
covid-19
Rhea-AI Summary

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 8:00 a.m. ET. Investors can arrange virtual meetings through the conference coordinator. Tonix focuses on CNS and immunology treatments, with its lead CNS candidate, TNX-102 SL, in mid-Phase 3 for fibromyalgia. Positive efficacy data for its COVID-19 vaccine candidate, TNX-1800, was reported, while interim data for the RALLY trial is expected in Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
conferences
Tonix Pharmaceut

Nasdaq:TNXP

TNXP Rankings

TNXP Stock Data

108.05M
6.88M
3.32%
9.86%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHATHAM